New Findings from Phase 3 Trials of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa to be Revealed at EHSF 2024

Results from the latest analyses of bimekizumab phase 3 trials in patients with moderate to severe hidradenitis suppurativa (HS) will be presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (February 7-9, 2024). UCB, a global biopharmaceutical company, announced these findings.

The analyses demonstrated significant improvements in patients treated with bimekizumab over 48 weeks. Approximately seven out of ten patients achieved IHS4-55, indicating a notable reduction in abscesses, nodules, and draining tunnels. Moreover, bimekizumab treatment resulted in enhancements in overall lesion count and lesion clearance across different types of lesions and anatomical areas.

Patient-reported data revealed that the substantial clinical responses observed with bimekizumab translated into improvements in health-related quality of life. Emmanuel Caeymaex, Executive Vice President at UCB, expressed confidence in bimekizumab’s potential to make a meaningful difference for patients with HS.

Professor Tzellos from Nordland Hospital Trust, Norway, highlighted the achievement of IHS4-55, showcasing the reduction in inflammatory nodules, abscesses, and draining tunnels with bimekizumab treatment.

The studies, BE HEARD I and BE HEARD II, included an initial treatment period (Weeks 0–16) and a maintenance period (Weeks 16–48). Patients were randomized to receive different dosing regimens of bimekizumab or placebo.

Key highlights from the analyses presented at EHSF 2024 include:

  • Dichotomous IHS4: At Week 16, a greater proportion of patients achieved IHS4-55 with bimekizumab treatment compared to placebo. By Week 48, these responses were sustained or increased.
  • Lesion Count and Clearance: Bimekizumab treatment demonstrated improvements in overall lesion count and clearance across different lesion types and anatomical areas, with sustained or improved results over 48 weeks.
  • Depth of Response and Impact on Quality of Life: Patients achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) reported a better quality of life, with similar trends observed at Week 48.
  • Clinical Response Across Duration Quartiles: Patients treated with bimekizumab across different disease duration quartiles consistently achieved significant clinical responses, which were sustained over 48 weeks.

These findings underscore the potential of bimekizumab as a promising treatment option for moderate to severe HS, although its efficacy and safety in this indication have not yet been established or approved by regulatory authorities worldwide.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter